Brookline Capital Management Estimates XFOR Q3 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at Brookline Capital Management issued their Q3 2025 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a note issued to investors on Thursday, May 1st. Brookline Capital Management analyst L. Cann anticipates that the company will earn ($2.80) per share for the quarter. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

Other equities research analysts have also issued reports about the company. HC Wainwright upped their price target on X4 Pharmaceuticals from $1.50 to $7.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $90.00 price objective on shares of X4 Pharmaceuticals in a research note on Wednesday, March 26th.

X4 Pharmaceuticals Stock Down 2.4 %

Shares of NASDAQ XFOR opened at $3.22 on Monday. The stock has a market cap of $18.62 million, a PE ratio of -35.77 and a beta of 0.73. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 12-month low of $3.05 and a 12-month high of $34.20. The company has a 50-day moving average of $7.34 and a 200 day moving average of $13.00.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Thursday, May 1st. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($4.13) by $4.17. The business had revenue of $28.81 million during the quarter, compared to analyst estimates of $7.03 million.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds have recently made changes to their positions in XFOR. Cantor Fitzgerald L. P. purchased a new stake in shares of X4 Pharmaceuticals during the 4th quarter valued at approximately $30,000. Atria Wealth Solutions Inc. acquired a new stake in X4 Pharmaceuticals during the fourth quarter worth $44,000. Wells Fargo & Company MN raised its position in X4 Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock valued at $58,000 after purchasing an additional 26,763 shares during the period. Bank of America Corp DE lifted its stake in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of X4 Pharmaceuticals by 233.0% during the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company’s stock worth $134,000 after purchasing an additional 128,148 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.